2. Signaling Pathways
  3. Immunology/Inflammation
  4. NOD-like Receptor (NLR)

NOD-like Receptor (NLR)

NOD-like Receptor (NLR)

Related Products

PDF 0.66 MB

Nucleotide oligomerization domain (NOD)-like receptors (NLRs) are critical cytoplasmic pattern-recognition receptors (PRRs) that play an important role in the host innate immune response and immunity homeostasis. There are 23 NLR family members in humans and at least 34 NLR genes in mice. NLRs are expressed in many cell types including immune cells and epithelial cells, although certain NLR family members are expressed primarily in phagocytes including macrophages and neutrophils. The NLR family are most commonly classified according to their N-terminal domain, falling into one of four subfamilies; NLRA, NLRB, NLRC and NLRP.

The NLRs recognize various ligands from microbial pathogens (peptidoglycan, flagellin, viral RNA, fungal hyphae, etc.), host cells (ATPs, cholesterol crystals, uric acid, etc.), and environmental sources (alum, asbestos, silica, alloy particles, UV radiation, skin irritants, etc.). Most NLRs act as PRRs, recognizing the above ligands and activate inflammatory responses. However, some NLRs may not act as PRRs but instead respond to cytokines such as interferons. The activated NLRs show various functions that can be divided into four broad categories: inflammasome formation, signaling transduction, transcription activation, and autophagy.

NOD-like Receptor (NLR) Isoform Specific Products:

NOD-like Receptor (NLR) Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-132831A
    Selnoflast calcium
    		Inhibitor
    Selnoflast calcium (RO7486967 calcium), formerly somalix/RG6418/IZD334, is an orally active, potent, selective and reversible small molecule NLRP3 inflammasome inhibitor. Selnoflast calcium is a potent inhibitor of IL-1β release stimulated by NLRP3 activation in human Alzheimer's disease (AD) monocyte-derived macrophages. Selnoflast calcium is promising for research of AD and systemic inflammatory diseases, such as ulcerative colitis and chronic obstructive pulmonary disease.
    Selnoflast calcium
  • HY-150965
    NDT-30805
    		Inhibitor
    NDT-30805 is a selective NLRP3 inflammasome inhibitor. NDT-30805 is a triazolopyrimidinone derivative and inhibits IL-1β release in PBMCs with an IC50 of 0.013 μM. NDT-30805 can be used for the research of inflammation and innate immunity.
    NDT-30805
  • HY-132831B
    Selnoflast potassium
    		Inhibitor
    Selnoflast potassium (RO7486967 potassium), formerly somalix/RG6418/IZD334, is an orally active, potent, selective and reversible small molecule NLRP3 inflammasome inhibitor. Selnoflast potassium is a potent inhibitor of IL-1β release stimulated by NLRP3 activation in human Alzheimer's disease (AD) monocyte-derived macrophages. Selnoflast potassium is promising for research of AD and systemic inflammatory diseases, such as ulcerative colitis and chronic obstructive pulmonary disease.
    Selnoflast potassium
  • HY-170904
    NLRP3-IN-72
    		Inhibitor
    NLRP3-IN-72 (Compound 2) is a benzimidazole derivative. NLRP3-IN-72 exhibits anti-inflammatory and antioxidant activities. NLRP3-IN-72 has an IC50 of 0.3 μM for NLRP3 IL-1β, a PD50 of 0.4 μM for protecting against pyroptosis, and an EC50 of 0.6 μM for inducing HO-1.
    NLRP3-IN-72
  • HY-163744
    NLRP3-IN-42
    		Inhibitor
    NLRP3-IN-42 (compound H28) is a potent NLRP3 inhibitor with an KD value of 1.15 µM. NLRP3-IN-42 decreases the LPS (HY-D1056) induced protein expression of cleaved-caspase-1 (p20). NLRP3-IN-42 selectively inhibits IL-1β release.
    NLRP3-IN-42
  • HY-162846
    NLRP3-IN-44
    		Inhibitor
    NLRP3-IN-44 (compound P33) is a potent and orally active (approximately 62%) inhibitor of NLRP3, with the Kd of 17.5 nM. NLRP3-IN-44 plays an important for studying NLRP3 inflammasome-mediated diseases.
    NLRP3-IN-44
  • HY-168137
    NOD2 agonist 2
    		Agonist
    NOD2 agonist 2 (compound 23) enhanced the antigen presentation of mouse bone marrow-derived dendritic cells (BMDCs), highlighting its potential as a vaccine adjuvant.
    NOD2 agonist 2
  • HY-137553A
    β-Aminoarteether maleate
    		Inhibitor
    β-Aminoarteether maleate (SM934) is an Artemisinin derivative with orally active. β-Aminoarteether maleate can be used for inflammation and autoimmune disease research, such as lupus diseases.
    β-Aminoarteether maleate
  • HY-N0496R
    Ruscogenin (Standard)
    		Inhibitor
    Ruscogenin (Standard) is the analytical standard of Ruscogenin. This product is intended for research and analytical applications. Ruscogenin, an important steroid sapogenin derived from Ophiopogon japonicus, attenuates cerebral ischemia-induced blood-brain barrier dysfunction by suppressing TXNIP/NLRP3 inflammasome activation and the MAPK pathway. Ruscogenin exerts significant anti-inflammatory and anti-thrombotic activities. Ruscogenin has orally bioactivity.
    Ruscogenin (Standard)
  • HY-168503
    NLRP3-IN-54
    		Inhibitor
    NLRP3-IN-54 (Compound C4) is an NLRP3 inhibitor. NLRP3-IN-54 can significantly reduce the levels of active Caspase-1 and active IL-1β (IC50 = 0.805 μM), can be used for inflammation research.
    NLRP3-IN-54
  • HY-172134
    NLRP3-IN-70
    		Inhibitor
    NLRP3-IN-70 (Compound 5m) is an NLRP3 inflammasome inhibitor with low oral bioavailability. NLRP3-IN-70 can directly bind to the NACHT domain of the NLRP3 protein and block the interaction of NLRP3 and ASC, thus inhibiting ASC oligomerization and NLRP3 inflammasome assembly. NLRP3-IN-70 can be used in the research of sepsis and nonalcoholic steatohepatitis.
    NLRP3-IN-70
  • HY-W753593
    N4-Acetylcytidine-13C5
    N4-Acetylcytidine-13C5 is the 13C-labeled N4-Acetylcytidine (HY-W019670). N4-acetylcytidine (N4A) is an endogenous nucleoside metabolite from the degradation of tRNA. N4-Acetylcytidine is formed by N-acetyltransferase 10 and other enzymes. N4-acetylcytidine might sustain NLRP3 inflammasome activation via induction of HMGB1 expression and releasee. N4-Acetylcytidine modifies mRNA, tRNA and rRNA, affecting their stability, translation efficiency (such as enterovirus 71 RNA). N4-Acetylcytidine is used in the study of cancer, neuroinflammatory diseases, viral infections and obesity.
    N4-Acetylcytidine-<sup>13</sup>C<sub>5</sub>
  • HY-157555
    NLRP3-IN-29
    		Inhibitor
    NLRP3-IN-29(Compound 5M) is an inhibitor of NLR family pyrin domain containing 3 (NLRP3). NLRP3-IN-29 has the potential for blood-brain barrier permeability and inflammation inhibition both in vivo and in vitro. NLRP3-IN-29 can be used for research on Alzheimer's disease.
    NLRP3-IN-29
  • HY-N10312
    Yadanzigan
    		Inhibitor
    Yadanzigan (YDZG) is an anti-inflammatory agent and a NLRP3 inhibitor. Yadanzigan specifically inhibits NLRP3 activation via inhibiting NF-κB pathway and Reactive Oxygen Species production. Yadanzigan also moderates LPS (HY-D1056)-induced acute lung injury (ALI) in mice.
    Yadanzigan
  • HY-146802
    NLRP3-IN-9
    		Inhibitor
    NLRP3-IN-9 is a potent NLRP3 inhibitor. NLRP3-IN-9 inhibits IL-1β release. NLRP3-IN-9 reduces inflammation and mechanical hyperalgesia. NLRP3-IN-9 has the potential for the research of gout.
    NLRP3-IN-9
  • HY-163756
    NLRP3-IN-43
    		Inhibitor
    NLRP3-IN-43 (compound II-8) is a poteny inhibitor of NLRP3 inflammasome activation that binds to the LRR domain, and disrupts NLRP3-NEK7 interaction.
    NLRP3-IN-43
  • HY-172778
    HNW005
    		Inhibitor
    HNW005 is a dual inhibitor of NLRP3 inflammasome and urate transporter 1 (URAT1). It has a KD value of 204.6 nM and an IC50 of 1.7 μM for inhibiting NLRP3 inflammasome activation, and an IC50 of 6.4 μM for inhibiting uric acid transmembrane transport. When administered at a dose of 2 mg/kg in vivo, HNW005 can achieve a uric acid reduction rate of 64.8%. It can exert anti - inflammatory, analgesic, and uric acid - lowering activities by inhibiting the activation of NLRP3 inflammasome and uric acid transmembrane transport. HNW005 can be used in the research of gouty arthritis.
    HNW005
  • HY-163695
    NLRP3-IN-41
    		Inhibitor
    NLRP3-IN-41 (compd S-9) is an orally active and brain-penetrant NLRP3 inhibitor with anti-inflammatory activities, anti-neuroinflammatory effect and without obvious cytotoxicity. NLRP3-IN-41 inhibits the priming and activation stages of the NLRP3 inflammasome and can be used for inflammasome-related diseases research.
    NLRP3-IN-41
  • HY-168009
    NLRP3-IN-45
    		Inhibitor
    NLRP3-IN-45 (D6) is an inhibitor of NLRP3 inflammasome activation, inhibiting the activity of IL-1β (IC50=41.79 nM). NLRP3-IN-45 exerts its effects without affecting the initial stage of NLRP3 inflammasome activation. NLRP3-IN-45 specifically inhibits the activation of NLRP3 inflammasome in the LPS-induced acute lung injury (ALI) mouse model.
    NLRP3-IN-45
  • HY-163498
    NLRP3-IN-37
    		Inhibitor
    NLRP3-IN-37 (Compound 23) is a NLRP3 inhibitor (EC50: 5 nM). NLRP3-IN-37 can be used for NLRP3 related research, such as gout, pseudogout, CAPS, NASH fibrosis, heart failure, idiophathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease, Parkinson's Disease and traumatic brain injury.
    NLRP3-IN-37
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
NOD-like Receptor (NLR) Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.